The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-25), Clinuvel Pharmaceuticals's share price is
$9.82.
Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38. Therefore, Clinuvel Pharmaceuticals's PE Ratio (TTM) for today is 25.57.
The historical rank and industry rank for Clinuvel Pharmaceuticals's PE Ratio (TTM) or its related term are showing as below:
CLVLF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 22.57 Med: 60.63 Max: 144.38
Current: 25.57
During the past 13 years, the highest PE Ratio (TTM) of Clinuvel Pharmaceuticals was 144.38. The lowest was 22.57. And the median was 60.63.
CLVLF's PE Ratio (TTM) is ranked better than 52% of 250
companies
in the Biotechnology industry
Industry Median: 27.125
vs CLVLF: 25.57
As of today (2024-04-25), Clinuvel Pharmaceuticals's share price is $9.82.
Clinuvel Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38. Therefore, Clinuvel Pharmaceuticals's PE Ratio without NRI for today is 25.57.
During the past 13 years, Clinuvel Pharmaceuticals's highestPE Ratio without NRI was 144.38. The lowest was 22.57. And the median was 60.63.
Clinuvel Pharmaceuticals's EPS without NRI for the
six
months ended in Dec. 2023 was $0.14.
Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.38.
During the past 12 months, Clinuvel Pharmaceuticals's average EPS without NRIGrowth Rate was 10.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 21.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 14.20% per year.
During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was -120.60% per year. And the median was 11.80% per year.
Clinuvel Pharmaceuticals's EPS (Basic) for the
six
months ended in Dec. 2023 was $0.15.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.41.
Clinuvel Pharmaceuticals PE Ratio (TTM) Historical Data
The historical data trend for Clinuvel Pharmaceuticals's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clinuvel Pharmaceuticals's PE Ratio (TTM)
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals's PE Ratio (TTM) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's PE Ratio (TTM) falls into.
Clinuvel Pharmaceuticals PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Clinuvel Pharmaceuticals's PE Ratio (TTM) for today is calculated as
Clinuvel Pharmaceuticals's Share Price of today is $9.82.
For company reported semi-annually, Clinuvel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Clinuvel Pharmaceuticals (OTCPK:CLVLF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Clinuvel Pharmaceuticals PE Ratio (TTM) Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVLF has been successfully added to your 